AbbVie Presents Long-Term Skyrizi and Rinvoq IBD Data at UEG Week 2026

Long-term results for risankizumab and upadacitinib

AbbVie (NYSE: ABBV) said the congress, held October 17-20, will feature data from open-label extension and post-hoc analyses in moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). According to the company, the results add to the evidence on clinical and endoscopic outcomes over approximately three years.

In UC, the COMMAND study showed sustained clinical and endoscopic outcomes with up to three years of risankizumab maintenance treatment. At week 96 with the 180mg dose, as-observed clinical remission rates ranged from 54.0% to 73.1%, and endoscopic remission rates from 38.8% to 53.5%. These figures cover both advanced therapy-naïve and advanced therapy-experienced patients.

In Crohn's disease, as-observed analyses from the U-ENDURE study showed that clinical and endoscopic outcomes with upadacitinib were maintained through approximately four years of treatment. At Week 144, clinical remission was achieved by 78.9% of patients on 15 mg and 86.6% on 30 mg. Endoscopic remission was reached by 47.1% and 64.2% of patients, respectively.

Real-world evidence for upadacitinib

Interim results from the real-world UPlift study covered evaluable patients (N=497) with moderate to severe Crohn's disease. According to AbbVie, 70.2% achieved clinical response with upadacitinib within 12 weeks, and the median time to first response was 13 days.

A separate real-world claims analysis looked at patients (N=514) with UC or CD. Those who switched from a Tumor Necrosis Factor inhibitor (TNFi) to upadacitinib had lower rates of IBD-related hospitalizations (9.5% vs 16.3%) and surgery (6.9% vs 10.6%) over 12 months than patients who cycled to another TNFi.

Subcutaneous induction and ABBV-466

AbbVie will also present further findings from the Phase 3 AFFIRM study, which evaluates subcutaneous risankizumab induction and maintenance in Crohn's disease. AFFIRM results were first presented at the 2026 American College of Gastroenterology Annual Scientific Meeting. The UEG Week presentations add analyses by prior advanced therapy exposure and further describe outcomes in patients who responded to subcutaneous induction and continued treatment.

On August 27, 2026, AbbVie announced that it had submitted an application to the European Medicines Agency seeking approval of Skyrizi for subcutaneous induction in adult patients with moderately to severely active Crohn's disease.

In a late-breaking oral session on Monday, October 19, the company will present primary results and molecular profiling from the Phase 2a TARGET-CD study of ABBV-466. The title describes it as a novel dual-targeting therapy that leads to endoscopic remission in moderate-to-severe Crohn's disease.

What it means for clinicians and patients

Sofie Berg, therapeutic area head for immunology, international medical affairs at AbbVie, said Crohn's disease and ulcerative colitis are "chronic, lifelong conditions" and that understanding how patients respond over time and in everyday clinical practice is critical. She said the data "can help clinicians move toward favorable long-term outcomes for people living with IBD."

The package combines extended trial follow-up with real-world observations, which gives clinicians more information on durability of response beyond the initial treatment period. The ABBV-466 results are from an investigational therapy, and the source does not state any approval status for it.

Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.